Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Acorda Places Another Bet In Neurology With Biotie Tender

Executive Summary

Following the dissolution of its partnership with Sanofi, MannKind's next gambit is licensing its dry-powder delivery technology to new company Receptor Life Sciences. We also highlight our sister publication IN VIVO's deal of the year winners in the alliance, M&A and financing categories.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.

HBW Product Launches: Preminity, Dr. Formulated, Clear Focus, Zicam Immune, Synergy Plus

Garden of Life offers Triple Action Dr. Formulated; BasicBites Synergy Plus for oral care; Zicam extends to Daily Immune Support and Sleep + Immune Support with melatonin; Novastell launches Preminity for PMS; Prunelax in gummy; and lion’s mane mushroom in Clear Focus.

Medicare Price ‘Negotiation’ : Manufacturer Compliance Gets Tougher Enforcement Provision

As legislation authorizing Medicare price 'negotiation' clears the Senate and appears on its way toward enactment after years of efforts by US congressional Democrats, and opposition by Republicans and the pharmaceutical industry, the bill continues to be tweaked.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS057416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel